Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      QuantuMDx y Menarini anuncian un acuerdo de distribución exclusivo para la plataforma Q-POC™

      (PRNewsfoto/Menarini Industrie Farmaceutiche Riunite)

      News provided by

      Menarini Industrie Farmaceutiche Riunite

      Nov 02, 2022, 15:53 ET

      Share this article

      Share this article


      • El acuerdo cubrirá inicialmente el Reino Unido y Francia con potencial para expandirse a otros países europeos y en todo el mundo

      NEWCASTLE UPON TYNE, Inglaterra y FLORENCIA, Italia, 2 de noviembre de 2022 /PRNewswire/ -- QuantuMDx Group Limited ("QuantuMDx"), un desarrollador con sede en el Reino Unido de diagnósticos moleculares transformacionales de punto de necesidad, y A.Menarini Diagnostics S.r.I. (Menarini), se complacen en anunciar un acuerdo de distribución exclusivo para la plataforma Q-POC™ de QuantuMDx en el Reino Unido y Francia.

      Según los términos del acuerdo, Menarini comercializará, venderá y dará servicio a Q-POC™, el ensayo SARS-CoV-2 de QuantuMDx y su nueva prueba SARS-CoV-2, Flu A/B, RSV Respiratory Panel que la empresa lanzó a principios de este año. El acuerdo [de cinco años] cubrirá inicialmente la distribución al Reino Unido y Francia, con la posibilidad de expandirse a otros mercados.

      Jonathan O'Halloran, consejero delegado de QuantuMDx, dijo: "Este acuerdo con Menarini es un paso comercial significativo para QuantuMDx. Menarini no solo tiene una amplia red global, sino también su conocimiento específico en el país y su presencia en toda Europa y más allá, significa que son un excelente socio para nosotros. El acuerdo nos permitirá acelerar aún más las ventas comerciales de Q-POC™, llevando nuestra plataforma de diagnóstico molecular multiplex Point-of-Need a entornos clínicos y no clínicos en una serie de nuevos mercados. Espero trabajar de cerca con Menarini en lo que estoy seguro será una asociación muy exitosa".

      Fabio Piazzalunga, director global de Menarini Diagnostics S.r.I., comentó: "La reciente pandemia ha resaltado la importancia de poder diagnosticar enfermedades infecciosas con precisión y rapidez. La plataforma Q-POC™ de QuantuMDx, que puede proporcionar resultados en aproximadamente 30 minutos, permitirá a los profesionales de la salud tomar decisiones de tratamiento informadas y reducir el riesgo de transmisión. Menarini es pionera en la descentralización de las rutinas de diagnóstico y desarrolló competencias y tecnologías centrales al hacerlo. Estamos muy contentos de poder comenzar a proporcionar una plataforma tan innovadora a los laboratorios en Reino Unido y Francia".

      Acerca de QuantuMDx

      QuantuMDx es una empresa progresiva de tecnología médica apasionada por empoderar al mundo para controlar enfermedades y reducir el sufrimiento. QuantuMDx resuelve problemas de diagnóstico del mundo real mediante la creación de soluciones moleculares multiplex para el punto de necesidad.

      QuantuMDx tiene operaciones globales y asociaciones estratégicas, lo que lo mantiene a la vanguardia del diagnóstico molecular.

      Q-POC™ es un dispositivo de PCR multiplex rápido, fácil de usar y portátil de muestra para responder. Ha sido diseñado para su uso en una variedad de entornos de atención médica del mundo real.

      Q-POC™ y su primera prueba, un ensayo de detección múltiplex SARS-CoV-2, tienen la marca CE-IVD según la Directiva de diagnóstico in vitro (98/79/EC), lo que permite su uso dentro de la Unión Europea y el Reino Unido. El 26 de mayo, Q-POC recibió la marca CE bajo el IVDR (Reglamento UE 2017/746).

      QuantuMDx planea lanzar una gama de ensayos de pruebas multiplex sindrómicas en los próximos meses y años.

      Para obtener más información sobre QuantuMDx y Q-POC™, su sistema rápido de PCR en el punto de atención, visite: www.quantumdx.com.

      Acerca de A.Menarini Diagnostics, el toque humano de la tecnología:

      La compañía lleva más de 45 años dedicada a ayudar a los profesionales sanitarios a realizar diagnósticos seguros y sostenibles, mejorando la calidad de vida de las personas en todo el mundo.

      A.Menarini Diagnostics forma parte del Grupo Farmacéutico Menarini, fundado en 1886. Hoy está presente en 140 países de todo el mundo, cuenta con más de 17.000 empleados y tiene una facturación en 2021 de 3.922 millones de euros.

      Más información en: www.menarinidiagnostics.com.

      Logo - https://mma.prnewswire.com/media/1936226/Menarini_Diagnostics_Logo.jpg

      Modal title

      Also from this source

      Die Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten Patienten mit rezidiviertem/refraktärem aggressivem B-Zell-Non-Hodgkin-Lymphom bekannt

      Die Menarini Group und Ryvu Therapeutics geben auf der ASH-Jahrestagung 2026 die ersten klinischen Daten aus der Phase-II-Studie JASPIS-01 zu Dapolsertib (MEN1703, SEL24) bei stark vorbehandelten Patienten mit rezidiviertem/refraktärem aggressivem B-Zell-Non-Hodgkin-Lymphom bekannt

      („Menarini"), ein führendes internationales Pharma- und Diagnostikunternehmen, und Stemline Therapeutics, Inc. („Stemline"), eine hundertprozentige...

      El Grupo Menarini y Ryvu Therapeutics presentan los primeros datos del estudio JASPIS-01 sobre dapolsertib

      El Grupo Menarini y Ryvu Therapeutics presentan los primeros datos del estudio JASPIS-01 sobre dapolsertib

      El Grupo Menarini («Menarini»), una compañía farmacéutica y de diagnóstico líder a nivel internacional, y Stemline Therapeutics, Inc. («Stemline»)...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.